ASLAN Pharmaceuticals Pte Ltd

149 articles with ASLAN Pharmaceuticals Pte Ltd

• ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

  1/11/2021

  ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

• ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

  11/19/2020

  ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available fr

• ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/9/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities.

• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

  10/22/2020

  --     ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort --    ASLAN004 found to be well tolerated at 400mg dose , third cohort will test 600mg dose

• ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

  10/16/2020

  Withnanomolar potency against SARS-CoV-2, ASLAN003 is also being assessed for its potential as a novel therapeutic for COVID-19 and other viruses

• ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

  9/21/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis patients.

• ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference.

• 

  BioSpace Global Roundup, Aug. 27

  8/27/2020

  Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.

• ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 StudyInterim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020

  8/24/2020

  ASLAN Pharmaceuticals announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis.

• ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020

  8/7/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the BTIG Virtual Biotechnology Conference.

• ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer

  8/3/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer.

• ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

  7/17/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced further progress towards a primary listing on the Nasdaq Global Market and receipt of a Notice of Delisting from the Taipei Exchange, an expected step in the TPEx delisting process.

• ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  7/13/2020

  ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said : “As COVID-19 restrictions gradually lift in Singapore we expe

• ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/11/2020

  ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, reported financial results for the first quarter ended 31 March 2020 and provided an update on its clinical activities.

• UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19

  4/13/2020

  ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

• ASLAN Intends to Resume Screening as Soon as Government Restrictions are Lifted and is Taking Steps to Open Sites in Australia to Accelerate Recruitment

  4/13/2020

  ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  3/18/2020

  ASLAN Pharmaceuticals reported financial results for the quarter and full year ended 31 December 2019 and provided an update on its clinical activities.

• ASLAN Pharmaceuticals to Present at 9th Annual SVB Leerink Global Healthcare Conference

  2/24/2020

  ASLAN Pharmaceuticals Limited announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference.

• 

  Clinical Catch-Up: December 2-5

  12/9/2019

  It was, as usual, a pretty busy week in clinical trial news. Here’s a look.